Shots: Novartis to receive $20M (€17.9M) up front, regulatory and commercial milestones plus royalties on sales. Pharming to get exclusive rights to develop and commercialize Novartis’ CDZ173 (leniolisib). Additionally, Pharming […]readmore
Tags : Activated Phosphoinositide 3-kinase Delta Syndrome
Latest Posts
Categories
Related Topics
AbbVie
Acceptance
Acquire
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Boehringer Ingelheim
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Lilly
Merck
Novartis
P-III
patients
Pfizer
receives
Regeneron
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
Treat
Treatment
US